Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Ferriprox Generic Name & Formulations
Legal Class
Rx
General Description
Deferiprone 500mg, 1000mg; scored tabs.
Pharmacological Class
Iron chelating agent.
How Supplied
Tabs 500mg—100; 1000mg (three times a day)—50; 1000mg (twice a day)—50, 500; Oral soln 80mg/mL—250mL, 500mL; 100mg/mL—500mL
Manufacturer
Generic Availability
NO
Ferriprox Indications
Indications
Transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias.
Limitations of Use
The safety and efficacy for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or with Diamond Blackfan anemia have not been established.
Ferriprox Dosage and Administration
Adults and Children
<8yrs: not established. Individualize. Round dose to the nearest half-tab (250mg or 500mg). ≥8yrs: Initially 25mg/kg 3 times daily (total of 75mg/kg/day). Adjust dose to individual response and therapeutic goals; max 33mg/kg 3 times daily (total of 99mg/kg/day). Consider temporary dose interruption if serum ferritin falls consistently <500mcg/L.
Ferriprox Contraindications
Not Applicable
Ferriprox Boxed Warnings
Boxed Warning
Agranulocytosis and neutropenia.
Ferriprox Warnings/Precautions
Warnings/Precautions
Risk of neutropenia or fatal agranulocytosis. Measure ANC before starting therapy and monitor weekly during. Interrupt therapy if infection or neutropenia develops (ANC <1.5×109/L). If neutropenia occurs, obtain CBCs, WBCs, ANC, and platelets daily until recovery (ANC ≥1.5×109/L). Monitor serum ALT monthly; consider interruption if persistent increase in transaminase levels. Monitor serum ferritin every 2–3 months. Monitor plasma zinc and supplement if deficient. Embryo-fetal toxicity. Advise to use effective contraception during and for ≥6 months (females of reproductive potential) or ≥3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥2 weeks after the last dose).
Ferriprox Pharmacokinetics
See Literature
Ferriprox Interactions
Interactions
Avoid concomitant other drugs associated with neutropenia or agranulocytosis; if unavoidable, closely monitor ANC. Avoid concomitant UGT1A6 inhibitors (eg, diclofenac, probenecid, milk thistle). Allow ≥4-hour interval with antacids or mineral supplements containing polyvalent cations (eg, iron, aluminum, zinc).
Ferriprox Adverse Reactions
Adverse Reactions
Nausea, vomiting, abdominal pain, increased ALT/AST, arthralgia, neutropenia, chromaturia, pyrexia, bone pain, headache, pain in extremity, sickle cell anemia with crisis, back pain, oropharyngeal pain, nasopharyngitis, cough; agranulocytosis (manage appropriately if occurs; do not resume).
Ferriprox Clinical Trials
See Literature
Ferriprox Note
Not Applicable
Ferriprox Patient Counseling
See Literature
Images
